Skip to main content

Table 1 Characteristics of patients

From: Challenging clinical cases in HCV infection

Case # Gender Age Hemoglobinopaty Year of HCV diagnosis HCV genotype HCV-RNA (IU/l) Hemoglobin (g/dl) ALT (IU/l) Metavir score HCV therapy Duration of therapy (weeks) Response
3 F 35 Thalassemia mayor 1990 2a Baseline 3,590,000 Baseline 10.1 Baseline 112 F2 (estimated through liver elastography) Peg-Interferon 100 µg per week 24 Responder
       Week 4 nd Week 4   Week 4 61     
       Week 12 nd Week 12   Week 12 53     
       Week 24 nd Week 24   Week 24 Normal   Ribavirin 800 mg/day   
       End of treatment nd End of treatment   End of treatment Normal     
       Follow up nd Follow up   Follow up Normal     
4 M 38 Thalassemia mayor 1991 4 Baseline 18,900,000 Baseline 8.9 Baseline   F2 (estimated through liver elastography) Peg-Interferon 180 µg per week 24 Non responder
       Week 4 3810 Week 4   Week 4      
       Week 12 3830 Week 12   Week 12      
       Week 24 21,900 Week 24   Week 24    Ribavirin 800 mg/day   
       End of treatment 21,900 End of treatment   End of treatment      
       Follow up 3,350,000 Follow up   Follow up      
5 M 31 Drepanocytosis 1990 1b Baseline 745,000 Baseline 8.3 Baseline Twofold the normal F2 Peg-Interferon 100 µg per week 72 Responder
       Week 4 not available Week 4   Week 4      
       Week 12 34470 Week 12   Week 12      
       Week 24 nd Week 24   Week 24    Ribavirin 800 mg/day   
       End of treatment nd End of treatment   End of treatment      
       Follow up nd Follow up   Follow up      
6 F 42 Thalassemia mayor 1991 2a Baseline 3,430,000 Baseline 8.9 Baseline 106 F2 (estimated through liver elastography) Peg-Interferon 100 µg per week 24 Relapser
       Week 4 nd Week 4   Week 4      
       Week 12 nd Week 12   Week 12      
       Week 24 nd Week 24   Week 24    Ribavirin 800 mg/day   
       End of treatment nd End of treatment   End of treatment      
       Follow up 1,360,000 Follow up   Follow up